What Ocumeda does

Ocumeda, founded in 2019 in Canton Thurgau, Switzerland, and headquartered in Munich as ocumeda GmbH, operates a cloud-based teleophthalmology platform that connects certified partner opticians with a network of 35+ tele-ophthalmologists across Germany, Austria and Switzerland. Its flagship service, the Augen-Check-Up, combines in-store measurements (visual acuity, refraction, intraocular pressure via tonometer, fundus photography) at optical retail locations with remote specialist interpretation, delivering a colour-coded traffic-light result within 48 hours. The platform powers three product modules: the standard Augen-Check-Up, Augen-Check-Up Plus (which adds anterior segment imaging), and the Ocumeda Care Network for structured referrals to local ophthalmologists.

The business model is primarily B2B2C, charging optician partners a per-screening fee for each Augen-Check-Up performed and earning enterprise platform fees from strategic partners Fielmann Group and ZEISS Vision Care (which also embedded Ocumeda as the medical layer of its ZEISS EyeCare Network). Revenue is supplemented by insurance reimbursement flows in Switzerland (KPT covers up to 75% of the cost for Pulse policyholders; CSS covers from 2023). The company serves consumer end-users (predominantly 40+ demographic) seeking accessible preventive eye screening, optical retail chains and independent opticians seeking a medically validated upsell service, and ophthalmologists who gain asynchronous review capacity.

Ocumeda operates through 800+ partner optician locations across the DACH region and has completed more than 500,000 screenings, detecting 110,000+ abnormalities and 3,500+ urgent cases. It is backed by Fielmann Group and ZEISS Vision Care (which acquired a 10% stake at a €100 million valuation in October 2025). The company holds ISO 13485 certification, is GDPR-compliant with ISO/IEC 27001 and BSI C5 cloud infrastructure, and is undergoing a €600,000 UKE Hamburg clinical validation study funded by Fielmann.

Name

Ocumeda

Legal name

ocumeda GmbH

Website

https://ocumeda.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Ocumeda operates a cloud teleophthalmology platform connecting 800+ DACH partner opticians with 35+ remote ophthalmologists to deliver the Augen-Check-Up, a low-threshold preventive eye screening service powered by Fielmann and ZEISS distribution.

Ownership category

akta.pro rank

Product category

Teleophthalmology / Preventive Eye Care Screening

NAICS

Offices of Optometrists (62132)

akta.pro primary industry

Ophthalmology & Vision Telemedicine Platforms (HLALAGAL)

akta.pro secondary industries

Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI), Optometry Clinics (Primary Eye Care) (HLAKAKAB)

Keywords

• Teleophthalmology platform
• Preventive eye screening
• Medical eye examinations
• Retinal image analysis
• Optical retail services

Headquarters

HQ city

Erlen

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Per-Screening Fees (B2B to Opticians): Ocumeda charges optician partners (optical retail chains and independent stores) a fee for each Augen-Check-Up conducted using the Ocumeda platform. The screening data is collected by trained optician staff and transmitted to Ocumeda's tele-ophthalmologist network for interpretation. Revenue is generated on a per-transaction basis per screening performed.
2. Insurance Reimbursement (Switzerland): In Switzerland, the Ocumeda Augen-Check-Up is covered by health insurance KPT for patients with Pulse Top or Pulse Premium supplementary insurance (up to 75% cost reimbursement). This creates a reimbursement revenue stream alongside the consumer self-pay model, reducing patient out-of-pocket cost.
3. B2B Enterprise Platform Licensing: Ocumeda provides its teleophthalmology platform to enterprise customers such as ZEISS Vision Care (ZEISS EyeCare Network) and Fielmann Group, where Ocumeda acts as the underlying medical infrastructure. Revenue is derived from platform licensing and per-screening arrangements with these enterprise partners.
4. Premium Screening Upgrades (Augen-Check-Up Plus): The extended Augen-Check-Up Plus (adding anterior eye segment imaging) represents an upsell opportunity over the standard screening, allowing opticians to offer a more comprehensive premium service at a higher price point.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Ocumeda operates a cloud-based teleophthalmology platform that connects trained partner opticians with a network of certified remote ophthalmologists to deliver low-threshold preventive eye screenings. The core Augen-Check-Up service captures fundus photography, intraocular pressure, visual acuity and refraction data at optical retail locations and transmits it for physician interpretation, with results delivered to patients within 48 hours via a traffic-light reporting system. Extended offerings include anterior segment imaging (Augen-Check-Up Plus), structured ophthalmologist referrals (Care Network), and partner optician enablement (Empower).

Product overview

Ocumeda operates a modular teleophthalmology platform centered on the Augen-Check-Up, a preventive eye screening service that connects partner opticians with remote ophthalmologists. The core Augen-Check-Up performs fundus photography, intraocular pressure measurement, and visual acuity testing, evaluated by a network of 35 tele-ophthalmologists. Three add-on modules extend the platform: Augen-Check-Up Plus adds anterior segment imaging for a broader anatomical assessment; Ocumeda Care Network facilitates structured referrals to local ophthalmologists for patients with abnormal findings; and Ocumeda Empower provides training, marketing, and consulting to strengthen partner opticians' preventive care capabilities. The platform is available at over 800 partner optician locations across Germany, Austria, and Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

• Ocumeda Augen-Check-Up: The core teleophthalmological eye screening service offered at partner opticians, involving measurements of visual acuity, refraction, intraocular pressure, and fundus photography, analyzed by ophthalmologists.
• Augen-Check-Up Plus
• Ocumeda Care Network
• Ocumeda Empower

Products and services

• Augen-Check-Up (Eye Check-Up) The flagship teleophthalmology screening service that enables partner opticians to perform preventive eye health checks using fundus photography, intraocular pressure measurement, and visual acuity testing, with remote evaluation by licensed ophthalmologists from Germany, Austria, and Switzerland. Results are delivered to patients within 48 hours via a colour-coded traffic-light reporting system.
• Augen-Check-Up Plus An enhanced version of the standard Augen-Check-Up that additionally captures and evaluates the anterior segment of the eye (eyelids, conjunctiva, cornea, iris, lens), enabling a broader medical screening alongside the existing fundus and intraocular pressure assessment.
• Ocumeda Care Network A care coordination platform that connects eye check-up participants with abnormal findings to nearby ophthalmologists, enabling opticians to integrate local eye doctor partnerships into their service offering and facilitating structured patient referral and follow-up.
• Ocumeda Empower A partner support program providing opticians with training (Ocumeda Academy), marketing assets, automated customer re-invitation tools, and consulting to help them establish and grow their preventive eye health service offering.
• ZEISS EyeCare Network (Ocumeda-powered platform) White-label teleophthalmology platform embedded in the ZEISS EyeCare Network, connecting ZEISS partner opticians (using ZEISS VISUREF 1000 devices) with the Ocumeda tele-ophthalmologist network for preventive eye health checks.

Quantifiable outcome

• Over 110,000 abnormalities detected from 500,000 screenings (~22% detection rate)
• +4 more outcomes

Named customers9 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• KPT (Swiss Health Insurance)coreStrategic or Co-development Partner · 8 April 2026KPT, one of the ten largest Swiss health insurers (~500,000 policyholders), added the Ocumeda Augen-Check-Up to its supplementary insurance (Pulse) benefit list under 'Früherkennung und Diagnostik'. Patients with Pulse Top or Pulse Premium coverage receive up to 75% cost reimbursement. Available at ~50 Ocumeda locations in Switzerland.
• Universitätsklinikum Hamburg-Eppendorf (UKE)majorStrategic or Co-development Partner · 4 November 2025UKE is conducting a €600,000 medical study (funded by Fielmann Group) to scientifically validate the Ocumeda-based eye check-up screening service. The study compares screening results from Fielmann locations in Hamburg metropolitan area with comprehensive examinations at UKE. Results expected end of 2027. Led by Prof. Dr. Martin Spitzer, Director of the UKE Eye Clinic.
• ZEISS Vision Care (ZEISS EyeCare Network)coreStrategic or Co-development Partner · 31 January 2025Ocumeda serves as the medical platform powering the ZEISS EyeCare Network. ZEISS Vision Care distributes Ocumeda's Augen-Check-Up to its partner opticians using ZEISS VISUREF 1000 devices. The platform connects optical retail stores with ophthalmologists for preventive eye health checks. Launched in Germany March 2025; Austria and Switzerland in H2 2025. Uses a traffic-light system to flag findings related to diabetic retinopathy, AMD and glaucoma.
• Fielmann GroupcoreStrategic or Co-development Partner · 18 October 2023Strategic partnership to offer the Ocumeda Augen-Check-Up at Fielmann branches across Germany and Switzerland. Following a successful pilot phase, the service was rolled out to 100+ Fielmann locations by end of 2023, and has since expanded to all Fielmann branches in Germany, Austria and Switzerland. Over 300,000 Fielmann customers have used the service. Fielmann co-funded a €600,000 clinical validation study at UKE.
• CSS Versicherung (Swiss Health Insurance)coreStrategic or Co-development Partner · 1 January 2023CSS, one of the largest Swiss health insurers, began covering Ocumeda Augen-Check-Up costs for its policyholders starting in 2023. This partnership made Ocumeda's screening service accessible through health insurance reimbursement in Switzerland, prior to the KPT partnership.
• UnternehmerTUMminorOthersUnternehmerTUM, Germany's largest centre for business and innovation, is listed as a partner and supporter of Ocumeda. The nature of the partnership is not explicitly detailed beyond the logo placement on Ocumeda's website.
• ACTO e.V. (Aachener Centrum für Technologietransfer in der Ophthalmologie)minorStrategic or Co-development PartnerOcumeda developed its concept in collaboration with ACTO e.V. and leading German ophthalmologists. ACTO co-authored the scientific whitepaper (Weißbuch) describing the clinical and scientific background of the Ocumeda Augen-Check-Up.

Scale indicators9 records

Recent moves10 records

Expansion highlights6 records

Emerging players

• AEYE Health: Israel-based AI company developing FDA-cleared autonomous screening for diabetic retinopathy and other retinal diseases from fundus photography. Comparable to Ocumeda as a younger AI teleophthalmology competitor targeting optometry and primary care workflows.
• RetinAI: Switzerland-based AI health-tech company building ophthalmology data management and AI image analysis tools (RetinAI Discovery, Discovery AIR) used by clinics and pharma. Comparable to Ocumeda as a fellow Swiss-based AI-ophthalmology player addressing disease detection from retinal imaging, though RetinAI is more B2B/research-oriented.

Broad incumbents

• Heidelberg Engineering: Germany-based ophthalmic diagnostic imaging company (Heidelberg Retina Tomograph, SPECTRALIS OCT) widely used in clinical ophthalmology. Comparable as a domestic German incumbent in ophthalmic diagnostic imaging whose installed base represents both a potential integration partner and a potential competitor moving toward AI-enabled screening.
• Optos (Nikon): UK-based (now part of Nikon) ultra-widefield retinal imaging company whose devices are deployed in optometry and ophthalmology practices globally. Comparable as an incumbent retinal imaging hardware vendor relevant to Ocumeda's screening workflow and as a potential vertical competitor in AI-enhanced screening.
• Topcon Healthcare: Japan-headquartered global ophthalmic device and software company producing fundus cameras, OCT, and clinical data management systems used in teleophthalmology workflows. Comparable as a vertically integrated incumbent supplying both the imaging hardware (similar to ZEISS VISUREF 1000) and software infrastructure that Ocumeda integrates with.

Direct peers

• Eyenuk: US-based developer of the EyeArt AI system for autonomous detection of diabetic retinopathy from fundus images, used in primary care and optometry settings. Closely comparable to Ocumeda's AI-assisted teleophthalmology screening model, though Eyenuk focuses on a single disease (DR) and US regulatory pathway (FDA-cleared).
• Smart Optometry: Slovenia-based developer of mobile eye-screening applications used by optometrists and ophthalmologists for visual acuity, contrast, color vision and basic functional tests. Comparable as a peer in optometry-facing digital screening tools, though with a software/app-only model rather than a full teleophthalmology service.
• Digital Diagnostics: US company (formerly IDx) that pioneered FDA-authorized autonomous AI diagnostic systems (IDx-DR) for diabetic retinopathy screening at point-of-care. Comparable as a direct AI teleophthalmology competitor with regulatory clearance and a similar optometry/primary-care distribution thesis.
• Visibly: US-based online vision test platform enabling refractive prescription renewal via remote optometrist review. Comparable as a tele-optometry screening service routed through digital channels, though US-focused and oriented to prescription renewal rather than disease detection.

Regional players

• Doctolib: France/Germany-headquartered leading European telehealth and practice-management platform with a strong German user base. Comparable as a broader European digital-health player operating in the same DACH regulatory and reimbursement environment, though Doctolib focuses on appointment booking and video consultations rather than teleophthalmology specifically.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ocumeda

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ocumeda